Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China, U.S. Drug Pact Addresses U.S. Security Issues (China)

This article was originally published in PharmAsia News

Executive Summary

U.S. concerns about the safety of drugs imported from China have as much to do with U.S. national security issues as with the safety of the medicines themselves. As an example, China and India are the only sources of key ingredients for two antibiotics considered the only ones suited to treat anthrax if an attack on the U.S. leaves the country short of supplies. The main component of anti-anthrax treatments, doxycycline, is made only in China. But drug-oversight scandals in China, which led to the execution of an official of the State FDA that oversees a $65 billion pharmaceutical industry, are seen as potential problems for the United States. (Click here for more ) "China's Monopoly On Pharmaceuticals Raises U.S., Europe Security Concerns" Taiwan News (12/10/07)

You may also be interested in...



Creating Stability In A Time Of Transition

UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.

Regulatory Measures Could Mitigate EU Coronavirus Risks

As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.

EU Off-Patent Industry Sees ‘Limited Immediate Risk’ From COVID-19

 The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.

UsernamePublicRestriction

Register

SC065848

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel